We take issue with the stance that postoperative radioiodine remnant ablation should be applied ubiquitously as adjuvant therapy in patients with well-differentiated thyroid carcinoma. In this article, we state the reasons that we believe a compelling case can be made against ablation in most patients.
- Radionuclide therapy
- Thyroid carcinoma
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging